Systematic Review: What CBD Does (and Does Not) Do in Humans
A systematic review of 34 human studies found preliminary evidence that high-dose oral CBD (150-600 mg/day) may help with social anxiety, insomnia, and epilepsy, while CBD's interaction with THC varied depending on route of administration.
Quick Facts
What This Study Found
The review identified 34 studies: 16 in healthy subjects and 18 in clinical populations covering MS, schizophrenia, bipolar mania, social anxiety, pain, cancer, Huntington's disease, insomnia, and epilepsy.
Key findings included: high inhaled/IV doses of CBD were needed to block THC effects. Oral/oromucosal CBD sometimes prolonged or intensified THC effects (contradicting the common belief that CBD always counteracts THC). Preliminary clinical evidence supported CBD for social anxiety disorder, insomnia, and epilepsy at doses of 150-600 mg/day, but mental sedation was a concern.
Key Numbers
34 studies reviewed (16 experimental, 18 clinical). Clinical conditions: MS (6), schizophrenia/bipolar (4), social anxiety (2), pain (2), cancer anorexia (1), Huntington's (1), insomnia (1), epilepsy (1). Therapeutic dose range: 150-600 mg/day oral.
How They Did This
Systematic review searching PubMed and EMBASE for "cannabidiol." Included randomized and crossover studies in healthy controls and clinical patients. Both CBD monotherapy and CBD+THC combination studies were included. 34 studies met inclusion criteria.
Why This Research Matters
This was one of the first comprehensive systematic reviews of CBD's effects in humans, providing a reality check on both the hype and skepticism surrounding CBD. The finding that CBD can sometimes enhance rather than counteract THC is particularly important for patients using combination products.
The Bigger Picture
This review captured CBD research at an inflection point. By 2012, enough human data existed to see genuine therapeutic signals, but the evidence was preliminary and the dose-response relationships were complex. The review set the stage for the larger clinical trials that followed.
What This Study Doesn't Tell Us
Many of the included studies had small sample sizes. The clinical studies covered diverse conditions with different designs, making synthesis difficult. The review captured a relatively early stage of CBD clinical research when few large trials had been conducted.
Questions This Raises
- ?What are the optimal CBD doses for each therapeutic indication?
- ?Why does the route of administration change how CBD interacts with THC?
- ?Is the sedation at high doses a side effect or a therapeutic feature for conditions like insomnia?
Trust & Context
- Key Stat:
- 150-600 mg/day oral CBD showed therapeutic signals for anxiety, insomnia, and epilepsy
- Evidence Grade:
- Systematic review of 34 studies; provides moderate evidence though many included studies were small.
- Study Age:
- Published in 2012. CBD research has expanded enormously since, with FDA-approved Epidiolex for epilepsy and ongoing trials for other conditions.
- Original Title:
- Cannabidiol in humans-the quest for therapeutic targets.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 5(5), 529-52 (2012)
- Authors:
- Zhornitsky, Simon, Potvin, Stéphane(5)
- Database ID:
- RTHC-00641
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Does CBD counteract THC?
It is more complicated than commonly believed. This review found that inhaled or IV CBD at high doses can block THC effects, but oral or oromucosal CBD sometimes prolonged or intensified THC effects. The interaction depends on the route of administration, doses, and timing.
What conditions does CBD actually help with?
As of this 2012 review, the strongest preliminary evidence was for social anxiety disorder, insomnia, and epilepsy, all using high oral doses (150-600 mg/day). Evidence for other conditions existed but was more limited. Since this review, CBD (as Epidiolex) has been FDA-approved for certain epilepsy types.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- why-does-weed-make-you-sleepy-thc-sleep
- why-does-weed-make-you-paranoid-amygdala
- why-weed-energetic-or-sleepy-difference
- why-weed-makes-me-anxious-now-not-before
- thc-and-benzodiazepines-dangerous-overlap
- thc-and-melatonin-combine-sleep
- using-weed-to-sleep-every-night-long-term
- sleep-hygiene-cannabis-users
- cannabis-sleep-architecture-deep-rem
- weed-circadian-rhythm-body-clock
- weed-and-sleep-apnea
- cannabis-vs-sleep-aids-comparison
- edibles-for-sleep-dosing-timing
Cite This Study
https://rethinkthc.com/research/RTHC-00641APA
Zhornitsky, Simon; Potvin, Stéphane. (2012). Cannabidiol in humans-the quest for therapeutic targets.. Pharmaceuticals (Basel, Switzerland), 5(5), 529-52. https://doi.org/10.3390/ph5050529
MLA
Zhornitsky, Simon, et al. "Cannabidiol in humans-the quest for therapeutic targets.." Pharmaceuticals (Basel, 2012. https://doi.org/10.3390/ph5050529
RethinkTHC
RethinkTHC Research Database. "Cannabidiol in humans-the quest for therapeutic targets." RTHC-00641. Retrieved from https://rethinkthc.com/research/zhornitsky-2012-cannabidiol-in-humansthe-quest
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.